

**37-7-306. Clinical pharmacist practitioner qualifications.** (1) A clinical pharmacist practitioner is a licensed pharmacist in good standing who:

(a) is certified by the board, in concurrence with the board of medical examiners, to provide drug therapy management, including initiating, modifying, or discontinuing therapies, identifying and managing drug-related problems, or ordering tests under the direction or supervision of a prescriber;

(b) has additional education, experience, or certification as required by the board in concurrence with the board of medical examiners; and

(c) has in place a collaborative pharmacy practice agreement.

(2) Only a pharmacist certified by the board may legally be identified as a clinical pharmacist practitioner.

24.174.526 : REQUIREMENTS TO BECOME A CLINICAL PHARMACIST PRACTI... Page 1 of 1



Linda McCulloch  
MONTANA SECRETARY OF STATE

[HOME](#) [SEARCH](#) [ABOUT US](#) [CONTACT US](#) [HELP](#)

**Rule: 24.174.526**

Rule Title: REQUIREMENTS TO BECOME A CLINICAL PHARMACIST PRACTITIONER

Department: [LABOR AND INDUSTRY](#)  
Chapter: [BOARD OF PHARMACY](#)  
Subchapter: [Licensing](#)

[Prev](#) [Up](#) [Next](#)



[Add to Favorites](#)

Latest version of the adopted rule presented in Administrative Rules of Montana (ARM):

[Printer Friendly Version](#)

**24.174.526 REQUIREMENTS TO BECOME A CLINICAL PHARMACIST PRACTITIONER**

(1) An applicant for a clinical pharmacist practitioner registration shall:

(a) submit an application on a form prescribed by the board;

(b) pay a registration fee as prescribed by the board;

(c) hold an active, unrestricted Montana pharmacist license;

(d) have completed five years of clinical practice experience or have completed a pharmacy residency and two years clinical practice experience and hold one of the following active certifications:

(i) BPS certification; or

(ii) nationally recognized certification in an area of practice as approved by the board and Board of Medical Examiners (BME).

(e) submit a signed collaborative practice agreement to the board that includes a description of the type of supervision the collaborating physician will exercise over the clinical pharmacist practitioner;

(f) following approval of the board, submit the application and collaborative practice agreement to the BME for approval; and

(g) appear before the board and/or BME if requested.

(2) Within ten days of discontinuing work under an approved collaborative drug therapy agreement, the pharmacist shall notify the board and the clinical pharmacist practitioner's registration shall be inactive, until such time as a new application is approved.

History: [37-7-201](#), MCA; [IMP](#), [37-7-201](#), [37-7-306](#), MCA; [NEW](#), 2010 MAR p. 2968, Eff. 12/24/10.